Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 137


RBX2 maintains final retinal cell position in a DAB1-dependent and -independent fashion.

Fairchild CL, Hino K, Han JS, Miltner AM, Peinado Allina G, Brown CE, Burns ME, La Torre A, Simó S.

Development. 2018 Feb 2;145(3). pii: dev155283. doi: 10.1242/dev.155283.


Pharmacology of smac mimetics; chemotype differentiation based on physical association with caspase regulators and cellular transport.

Talbott RL, Borzilleri RM, Chaudhry C, Fargnoli J, Shen H, Fairchild C, Barnhart B, Ortega M, McDonagh TE, Vuppugalla R, Vite GD, Hunt JT, Gottardis M, Naglich JG.

Exp Cell Res. 2015 Nov 1;338(2):251-60. doi: 10.1016/j.yexcr.2015.08.011. Epub 2015 Aug 21.


Sensitivity of Small Cell Lung Cancer to BET Inhibition Is Mediated by Regulation of ASCL1 Gene Expression.

Lenhart R, Kirov S, Desilva H, Cao J, Lei M, Johnston K, Peterson R, Schweizer L, Purandare A, Ross-Macdonald P, Fairchild C, Wong T, Wee S.

Mol Cancer Ther. 2015 Oct;14(10):2167-74. doi: 10.1158/1535-7163.MCT-15-0037. Epub 2015 Aug 7.


IRS2 copy number gain, KRAS and BRAF mutation status as predictive biomarkers for response to the IGF-1R/IR inhibitor BMS-754807 in colorectal cancer cell lines.

Huang F, Chang H, Greer A, Hillerman S, Reeves KA, Hurlburt W, Cogswell J, Patel D, Qi Z, Fairchild C, Ryseck RP, Wong TW, Finckenstein FG, Jackson J, Carboni JM.

Mol Cancer Ther. 2015 Feb;14(2):620-30. doi: 10.1158/1535-7163.MCT-14-0794-T. Epub 2014 Dec 19.


Specialized filopodia: at the 'tip' of morphogen transport and vertebrate tissue patterning.

Fairchild CL, Barna M.

Curr Opin Genet Dev. 2014 Aug;27:67-73. doi: 10.1016/j.gde.2014.03.013. Epub 2014 Jun 5. Review.


FoxD3 regulates cranial neural crest EMT via downregulation of tetraspanin18 independent of its functions during neural crest formation.

Fairchild CL, Conway JP, Schiffmacher AT, Taneyhill LA, Gammill LS.

Mech Dev. 2014 May;132:1-12. doi: 10.1016/j.mod.2014.02.004. Epub 2014 Feb 28.


Carcinogenicity risk assessment supports the chronic safety of dapagliflozin, an inhibitor of sodium-glucose co-transporter 2, in the treatment of type 2 diabetes mellitus.

Reilly TP, Graziano MJ, Janovitz EB, Dorr TE, Fairchild C, Lee F, Chen J, Wong T, Whaley JM, Tirmenstein M.

Diabetes Ther. 2014 Jun;5(1):73-96. doi: 10.1007/s13300-014-0053-3. Epub 2014 Jan 29.


Design, synthesis, functional and structural characterization of an inhibitor of N-acetylneuraminate-9-phosphate phosphatase: observation of extensive dynamics in an enzyme/inhibitor complex.

Kim SH, Constantine KL, Duke GJ, Goldfarb V, Hunt JT, Johnson S, Kish K, Klei HE, McDonnell PA, Metzler WJ, Mueller L, Poss MA, Fairchild CR, Bhide RS.

Bioorg Med Chem Lett. 2013 Jul 15;23(14):4107-11. doi: 10.1016/j.bmcl.2013.05.052. Epub 2013 May 23.


Tetraspanin18 is a FoxD3-responsive antagonist of cranial neural crest epithelial-to-mesenchymal transition that maintains cadherin-6B protein.

Fairchild CL, Gammill LS.

J Cell Sci. 2013 Mar 15;126(Pt 6):1464-76. doi: 10.1242/jcs.120915. Epub 2013 Feb 15.


Bromophycoic acids: bioactive natural products from a Fijian red alga Callophycus sp.

Teasdale ME, Shearer TL, Engel S, Alexander TS, Fairchild CR, Prudhomme J, Torres M, Le Roch K, Aalbersberg W, Hay ME, Kubanek J.

J Org Chem. 2012 Sep 21;77(18):8000-6. Epub 2012 Sep 5.


Outcomes and cost comparison of three therapeutic approaches to allergic rhinitis.

Fairchild CJ, Durden E, Cao Z, Smale P.

Am J Rhinol Allergy. 2011 Jul-Aug;25(4):257-62. doi: 10.2500/ajra.2011.25.3636. Epub 2011 May 31.


Antitumor and antiangiogenic activities of BMS-690514, an inhibitor of human EGF and VEGF receptor kinase families.

Wong TW, Lee FY, Emanuel S, Fairchild C, Fargnoli J, Fink B, Gavai A, Hammell A, Henley B, Hilt C, Hunt JT, Krishnan B, Kukral D, Lewin A, Malone H, Norris D, Oppenheimer S, Vite G, Yu C.

Clin Cancer Res. 2011 Jun 15;17(12):4031-41. doi: 10.1158/1078-0432.CCR-10-3417. Epub 2011 Apr 29.


Comprehensive report of olopatadine 0.6% nasal spray as treatment for children with seasonal allergic rhinitis.

Meltzer EO, Blaiss M, Fairchild CJ.

Allergy Asthma Proc. 2011 May-Jun;32(3):213-20. doi: 10.2500/aap.2011.32.3448. Epub 2011 Apr 8.


The economic burden of dry eye disease in the United States: a decision tree analysis.

Yu J, Asche CV, Fairchild CJ.

Cornea. 2011 Apr;30(4):379-87. doi: 10.1097/ICO.0b013e3181f7f363.


Structure and biological evaluation of novel cytotoxic sterol glycosides from the marine red alga Peyssonnelia sp.

Lin AS, Engel S, Smith BA, Fairchild CR, Aalbersberg W, Hay ME, Kubanek J.

Bioorg Med Chem. 2010 Dec 1;18(23):8264-9. doi: 10.1016/j.bmc.2010.10.010. Epub 2010 Oct 28.


Imaging utilization: an interdisciplinary workshop for nurse practitioner students.

Hall MA, Fairchild CE, McBride JA, Titzer JL, Wilson AL, Hiam JP.

Nurse Educ. 2010 Nov-Dec;35(6):234-6. doi: 10.1097/NNE.0b013e3181f7ef65. No abstract available.


Unusual antimalarial meroditerpenes from tropical red macroalgae.

Stout EP, Prudhomme J, Roch KL, Fairchild CR, Franzblau SG, Aalbersberg W, Hay ME, Kubanek J.

Bioorg Med Chem Lett. 2010 Oct 1;20(19):5662-5. doi: 10.1016/j.bmcl.2010.08.031. Epub 2010 Aug 10.


Ecological leads for natural product discovery: Novel sesquiterpene hydroquinones from the red macroalga Peyssonnelia sp.

Lane AL, Mular L, Drenkard EJ, Shearer TL, Engel S, Fredericq S, Fairchild CR, Prudhomme J, Le Roch K, Hay ME, Aalbersberg W, Kubanek J.

Tetrahedron. 2010 Jan 9;66(2):455-461.


Bioactive bromophycolides R-U from the Fijian red alga Callophycus serratus.

Lin AS, Stout EP, Prudhomme J, Le Roch K, Fairchild CR, Franzblau SG, Aalbersberg W, Hay ME, Kubanek J.

J Nat Prod. 2010 Feb 26;73(2):275-8. doi: 10.1021/np900686w.


Developmental cues and persistent neurogenic potential within an in vitro neural niche.

Pierret C, Morrison JA, Rath P, Zigler RE, Engel LA, Fairchild CL, Shi H, Maruniak JA, Kirk MD.

BMC Dev Biol. 2010 Jan 14;10:5. doi: 10.1186/1471-213X-10-5.


Discovery of anticancer agents of diverse natural origin.

Kinghorn AD, Carcache de Blanco EJ, Chai HB, Orjala J, Farnsworth NR, Soejarto DD, Oberlies NH, Wani MC, Kroll DJ, Pearce CJ, Swanson SM, Kramer RA, Rose WC, Fairchild CR, Vite GD, Emanuel S, Jarjoura D, Cope FO.

Pure Appl Chem. 2009 Jan 1;81(6):1051-1063.


Antimalarial bromophycolides J-Q from the Fijian red alga Callophycus serratus.

Lane AL, Stout EP, Lin AS, Prudhomme J, Le Roch K, Fairchild CR, Franzblau SG, Hay ME, Aalbersberg W, Kubanek J.

J Org Chem. 2009 Apr 3;74(7):2736-42. doi: 10.1021/jo900008w.


United States cost-effectiveness study of two dry eye ophthalmic lubricants.

Wlodarczyk J, Fairchild C.

Ophthalmic Epidemiol. 2009 Jan-Feb;16(1):22-30. doi: 10.1080/09286580802521309.


BMS-536924 reverses IGF-IR-induced transformation of mammary epithelial cells and causes growth inhibition and polarization of MCF7 cells.

Litzenburger BC, Kim HJ, Kuiatse I, Carboni JM, Attar RM, Gottardis MM, Fairchild CR, Lee AV.

Clin Cancer Res. 2009 Jan 1;15(1):226-37. doi: 10.1158/1078-0432.CCR-08-0801.


Synergistic antitumor activity of ixabepilone (BMS-247550) plus bevacizumab in multiple in vivo tumor models.

Lee FY, Covello KL, Castaneda S, Hawken DR, Kan D, Lewin A, Wen ML, Ryseck RP, Fairchild CR, Fargnoli J, Kramer R.

Clin Cancer Res. 2008 Dec 15;14(24):8123-31. doi: 10.1158/1078-0432.CCR-08-0025.


Antibacterial neurymenolides from the Fijian red alga Neurymenia fraxinifolia.

Stout EP, Hasemeyer AP, Lane AL, Davenport TM, Engel S, Hay ME, Fairchild CR, Prudhomme J, Le Roch K, Aalbersberg W, Kubanek J.

Org Lett. 2009 Jan 1;11(1):225-8. doi: 10.1021/ol8024814.


Structures and absolute configurations of sulfate-conjugated triterpenoids including an antifungal chemical defense of the green macroalga Tydemania expeditionis.

Jiang RW, Lane AL, Mylacraine L, Hardcastle KI, Fairchild CR, Aalbersberg W, Hay ME, Kubanek J.

J Nat Prod. 2008 Sep;71(9):1616-9. doi: 10.1021/np800307h. Epub 2008 Sep 3.


Antineoplastic unsaturated fatty acids from Fijian macroalgae.

Jiang RW, Hay ME, Fairchild CR, Prudhomme J, Roch KL, Aalbersberg W, Kubanek J.

Phytochemistry. 2008 Oct;69(13):2495-500. doi: 10.1016/j.phytochem.2008.07.005. Epub 2008 Aug 29.


Clinically important difference in dry eye: change in IDEEL-symptom bother.

Fairchild CJ, Chalmers RL, Begley CG.

Optom Vis Sci. 2008 Aug;85(8):699-707. doi: 10.1097/OPX.0b013e3181824e0d.


Preclinical efficacy spectrum and pharmacokinetics of ixabepilone.

Lee FY, Smykla R, Johnston K, Menard K, McGlinchey K, Peterson RW, Wiebesiek A, Vite G, Fairchild CR, Kramer R.

Cancer Chemother Pharmacol. 2009 Jan;63(2):201-12. doi: 10.1007/s00280-008-0727-5. Epub 2008 Mar 19.


Preclinical discovery of ixabepilone, a highly active antineoplastic agent.

Lee FY, Borzilleri R, Fairchild CR, Kamath A, Smykla R, Kramer R, Vite G.

Cancer Chemother Pharmacol. 2008 Dec;63(1):157-66. doi: 10.1007/s00280-008-0724-8. Epub 2008 Mar 18. Review.


Cytotoxic xanthones from Psorospermum molluscum from the Madagascar rain forest.

Leet JE, Liu X, Drexler DM, Cantone JL, Huang S, Mamber SW, Fairchild CR, Hussain R, Newman DJ, Kingston DG.

J Nat Prod. 2008 Mar;71(3):460-3. doi: 10.1021/np070523l. Epub 2008 Feb 5.


Medication compliance and persistence: terminology and definitions.

Cramer JA, Roy A, Burrell A, Fairchild CJ, Fuldeore MJ, Ollendorf DA, Wong PK.

Value Health. 2008 Jan-Feb;11(1):44-7. doi: 10.1111/j.1524-4733.2007.00213.x. Review.


Comprehensive report of the efficacy, safety, quality of life, and work impact of Olopatadine 0.6% and Olopatadine 0.4% treatment in patients with seasonal allergic rhinitis.

Fairchild CJ, Meltzer EO, Roland PS, Wells D, Drake M, Wall GM.

Allergy Asthma Proc. 2007 Nov-Dec;28(6):716-23. doi: 10.2500/aap.2007.28.3062.


Marmycins A and B, cytotoxic pentacyclic C-glycosides from a marine sediment-derived actinomycete related to the genus Streptomyces.

Martin GD, Tan LT, Jensen PR, Dimayuga RE, Fairchild CR, Raventos-Suarez C, Fenical W.

J Nat Prod. 2007 Sep;70(9):1406-9. Epub 2007 Sep 11.


Callophycoic acids and callophycols from the Fijian red alga Callophycus serratus.

Lane AL, Stout EP, Hay ME, Prusak AC, Hardcastle K, Fairchild CR, Franzblau SG, Le Roch K, Prudhomme J, Aalbersberg W, Kubanek J.

J Org Chem. 2007 Sep 14;72(19):7343-51. Epub 2007 Aug 23.


Alvaradoins E-N, antitumor and cytotoxic anthracenone C-glycosides from the leaves of Alvaradoa haitiensis.

Phifer SS, Lee D, Seo EK, Kim NC, Graf TN, Kroll DJ, Navarro HA, Izydore RA, Jiménez F, Garcia R, Rose WC, Fairchild CR, Wild R, Soejarto DD, Farnsworth NR, Kinghorn AD, Oberlies NH, Wall ME, Wani MC.

J Nat Prod. 2007 Jun;70(6):954-61. Epub 2007 Jun 7.


Identification of candidate molecular markers predicting sensitivity in solid tumors to dasatinib: rationale for patient selection.

Huang F, Reeves K, Han X, Fairchild C, Platero S, Wong TW, Lee F, Shaw P, Clark E.

Cancer Res. 2007 Mar 1;67(5):2226-38.


Improved quality of life among seasonal allergic rhinitis patients treated with olopatadine HCl nasal spray 0.4% and olopatadine HCl nasal spray 0.6% compared with vehicle placebo.

Hampel FC Jr, Ratner PH, Amar NJ, van Bavel JH, Mohar D, Fairchild CJ, Wall GM, Brubaker MJ, Drake M, Crenshaw KM.

Allergy Asthma Proc. 2006 May-Jun;27(3):202-7.


The economic impact of blue-light filtering intraocular lenses on age-related macular degeneration associated with cataract surgery: a third-party payer's perspective.

Reddy P, Gao X, Barnes R, Fairchild C, Boci K, Waycaster C, Pashos C.

Curr Med Res Opin. 2006 Jul;22(7):1311-8.


Bromophycolides C-I from the Fijian red alga Callophycus serratus.

Kubanek J, Prusak AC, Snell TW, Giese RA, Fairchild CR, Aalbersberg W, Hay ME.

J Nat Prod. 2006 May;69(5):731-5.


Inhibitors of human mitotic kinesin Eg5: characterization of the 4-phenyl-tetrahydroisoquinoline lead series.

Tarby CM, Kaltenbach RF 3rd, Huynh T, Pudzianowski A, Shen H, Ortega-Nanos M, Sheriff S, Newitt JA, McDonnell PA, Burford N, Fairchild CR, Vaccaro W, Chen Z, Borzilleri RM, Naglich J, Lombardo LJ, Gottardis M, Trainor GL, Roussell DL.

Bioorg Med Chem Lett. 2006 Apr 15;16(8):2095-100. Epub 2006 Feb 3.


Differential effect of imipenem treatment on wild-type and NK cell-deficient CD8 knockout mice during acute intra-abdominal injury.

Enoh VT, Fairchild CD, Lin CY, Varma TK, Sherwood ER.

Am J Physiol Regul Integr Comp Physiol. 2006 Mar;290(3):R685-93. Epub 2005 Nov 3.


Antineoplastic diterpene-benzoate macrolides from the Fijian red alga Callophycus serratus.

Kubanek J, Prusak AC, Snell TW, Giese RA, Hardcastle KI, Fairchild CR, Aalbersberg W, Raventos-Suarez C, Hay ME.

Org Lett. 2005 Nov 10;7(23):5261-4.


Novel fluoro-substituted camptothecins: in vivo antitumor activity, reduced gastrointestinal toxicity and pharmacokinetic characterization.

Rose WC, Marathe PH, Jang GR, Monticello TM, Balasubramanian BN, Long B, Fairchild CR, Wall ME, Wani MC.

Cancer Chemother Pharmacol. 2006 Jul;58(1):73-85. Epub 2005 Oct 14.


Discovery of a fluoroindolo[2,3-a]carbazole clinical candidate with broad spectrum antitumor activity in preclinical tumor models superior to the marketed oncology drug, CPT-11.

Saulnier MG, Balasubramanian BN, Long BH, Frennesson DB, Ruediger E, Zimmermann K, Eummer JT, St Laurent DR, Stoffan KM, Naidu BN, Mahler M, Beaulieu F, Bachand C, Lee FY, Fairchild CR, Stadnick LK, Rose WC, Solomon C, Wong H, Martel A, Wright JJ, Kramer R, Langley DR, Vyas DM.

J Med Chem. 2005 Apr 7;48(7):2258-61.


Novel 3',6'-anhydro and N12,N13-bridged glycosylated fluoroindolo[2,3-a]carbazoles as topoisomerase I inhibitors. Fluorine as a leaving group from sp3 carbon.

Saulnier MG, Langley DR, Frennesson DB, Long BH, Huang S, Gao Q, Wu D, Fairchild CR, Ruediger E, Zimmermann K, St Laurent DR, Balasubramanian BN, Vyas DM.

Org Lett. 2005 Mar 31;7(7):1271-4.


Cardiovascular disease in U.S. patients with metabolic syndrome, diabetes, and elevated C-reactive protein.

Malik S, Wong ND, Franklin S, Pio J, Fairchild C, Chen R.

Diabetes Care. 2005 Mar;28(3):690-3.


Discovery of N-(2-chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin-4- ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays.

Lombardo LJ, Lee FY, Chen P, Norris D, Barrish JC, Behnia K, Castaneda S, Cornelius LA, Das J, Doweyko AM, Fairchild C, Hunt JT, Inigo I, Johnston K, Kamath A, Kan D, Klei H, Marathe P, Pang S, Peterson R, Pitt S, Schieven GL, Schmidt RJ, Tokarski J, Wen ML, Wityak J, Borzilleri RM.

J Med Chem. 2004 Dec 30;47(27):6658-61.


Fhit-deficient normal and cancer cells are mitomycin C and UVC resistant.

Ottey M, Han SY, Druck T, Barnoski BL, McCorkell KA, Croce CM, Raventos-Suarez C, Fairchild CR, Wang Y, Huebner K.

Br J Cancer. 2004 Nov 1;91(9):1669-77.

Supplemental Content

Loading ...
Support Center